- Home
- NBIX vs H Comparison
NBIX vs H Comparison
Compare NBIX & H Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBIX
- H
- Stock Information
- Founded
- NBIX 1992
- H 1957
- Country
- NBIX United States
- H United States
- Employees
- NBIX N/A
- H N/A
- Industry
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- H Hotels/Resorts
- Sector
- NBIX Health Care
- H Consumer Discretionary
- Exchange
- NBIX Nasdaq
- H Nasdaq
- Market Cap
- NBIX 14.4B
- H 13.9B
- IPO Year
- NBIX 1996
- H 2009
- Fundamental
- Price
- NBIX $150.87
- H $154.72
- Analyst Decision
- NBIX Strong Buy
- H Buy
- Analyst Count
- NBIX 18
- H 15
- Target Price
- NBIX $172.06
- H $156.87
- AVG Volume (30 Days)
- NBIX 1.0M
- H 1.1M
- Earning Date
- NBIX 10-28-2025
- H 11-06-2025
- Dividend Yield
- NBIX N/A
- H 0.39%
- EPS Growth
- NBIX 12.44
- H N/A
- EPS
- NBIX 4.19
- H N/A
- Revenue
- NBIX $2,682,700,000.00
- H $3,339,000,000.00
- Revenue This Year
- NBIX $23.68
- H $121.54
- Revenue Next Year
- NBIX $18.02
- H $4.88
- P/E Ratio
- NBIX $35.78
- H N/A
- Revenue Growth
- NBIX 19.61
- H N/A
- 52 Week Low
- NBIX $84.23
- H $102.43
- 52 Week High
- NBIX $157.67
- H $168.20
- Technical
- Relative Strength Index (RSI)
- NBIX 59.16
- H 64.30
- Support Level
- NBIX $133.62
- H $134.73
- Resistance Level
- NBIX $157.67
- H $156.01
- Average True Range (ATR)
- NBIX 4.58
- H 4.39
- MACD
- NBIX 0.98
- H 0.29
- Stochastic Oscillator
- NBIX 67.98
- H 94.07
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc engages in the discovery, development, and commercialization of drugs for the treatment of neurological and endocrine-related diseases and disorders in the United States. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.
About H Hyatt Hotels Corporation
Hyatt is an operator of owned (3% of total rooms) and managed and franchised (97%) properties across about 30 upscale luxury brands, which includes vacation brands (Apple Leisure Group, Hyatt Ziva, and Hyatt Zilara), the recently launched full-service lifestyle brand Hyatt Centric, the soft lifestyle brand Unbound, the wellness brand Miraval, and the midscale extended-stay brand Studios. Hyatt acquired Two Roads Hospitality in 2018 and Apple Leisure Group in 2021. The regional exposure as a percentage of total rooms is 63% Americas, 15% rest of world, and 22% Asia-Pacific.